| Literature DB >> 28399409 |
Luigi Leanza1, Matteo Romio2, Katrin Anne Becker3, Michele Azzolini4, Livio Trentin5, Antonella Managò1, Elisa Venturini3, Angela Zaccagnino6, Andrea Mattarei2, Luca Carraretto1, Andrea Urbani1, Stephanie Kadow3, Lucia Biasutto4, Veronica Martini5, Filippo Severin5, Roberta Peruzzo1, Valentina Trimarco5, Jan-Hendrik Egberts6, Charlotte Hauser6, Andrea Visentin5, Gianpietro Semenzato5, Holger Kalthoff6, Mario Zoratti4, Erich Gulbins7, Cristina Paradisi8, Ildiko Szabo9.
Abstract
The potassium channel Kv1.3 is highly expressed in the mitochondria of various cancerous cells. Here we show that direct inhibition of Kv1.3 using two mitochondria-targeted inhibitors alters mitochondrial function and leads to reactive oxygen species (ROS)-mediated death of even chemoresistant cells independently of p53 status. These inhibitors killed 98% of ex vivo primary chronic B-lymphocytic leukemia tumor cells while sparing healthy B cells. In orthotopic mouse models of melanoma and pancreatic ductal adenocarcinoma, the compounds reduced tumor size by more than 90% and 60%, respectively, while sparing immune and cardiac functions. Our work provides direct evidence that specific pharmacological targeting of a mitochondrial potassium channel can lead to ROS-mediated selective apoptosis of cancer cells in vivo, without causing significant side effects.Entities:
Keywords: ROS-induced apoptosis; bioenergetics; chronic lymphocytic leukemia; ion channels and cancer; mitochondrial metabolism; mitochondrial potassium channels; mitochondriotropic inhibitors; orthotopic melanoma model; pancreatic ductal adenocarcinoma; pharmacokinetics
Mesh:
Substances:
Year: 2017 PMID: 28399409 DOI: 10.1016/j.ccell.2017.03.003
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743